radius results: midostaurin reduces relapse after asct in flt3-itd aml
Published 5 years ago • 213 plays • Length 3:56Download video MP4
Download video MP3
Similar videos
-
2:12
midostaurin for newly diagnosed flt3 aml: radius-x efficacy and safety data
-
2:20
best treatment strategy for flt3 itd aml
-
3:42
midostaurin in c-kit or flt3-itd mutated t(8;21) aml
-
1:13
prevention, detection and treatment of aml relapse after allo-sct
-
1:35
flt3 inhibitor maintenance after allo-sct for aml
-
2:40
what we still don't know about the ratify study of midostaurin in aml
-
2:54
impact of mrd on flt3-itd aml
-
27:03
adjacent segment degeneration l2l3
-
53:10
rayos contra cancer hdr brachytherapy session 4: source strength measurements | adam shulman
-
8:43
management of st – elevation mi , time to thrombolysis, choosing and initiating reperfusion.
-
1:36
midostaurin and quizartinib: improving survival and day-to-day life in aml
-
2:28
midostaurin: the first drug to receive approval for aml since 2000
-
4:09
quantum-r: quizartinib looks promising for flt3-itd mutated aml
-
2:34
the effect of dose reduction of talquetamab in patients with r/r mm: results from monumental-1
-
4:25
recent developments in the mutational landscape and molecular basis of aml
-
2:30
flt3 inhibitors - their role in aml
-
2:46
role of flt3 inhibitors as maintenance following transplant in aml
-
2:22
inhibitors of flt3 flying into 2019: what to expect this year
-
4:39
aml & mds: mac or ric?
-
0:53
go-flag: bridge therapy to allo-sct in r/r aml
-
3:25
flt3 inhibitors as a strategy to treat aml
-
2:47
using artificial intelligence to estimate overall mortality and non-relapse mortality after allosct